Northern Trust Corp Pacira Bio Sciences, Inc. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 486,227 shares of PCRX stock, worth $7.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

486,227

Previous 510,745 4.8%

Holding current value

$7.07 Million

Previous $14.9 Million 6.79%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$25.5 - $31.51 $625,209 - $772,562	-24,518 Reduced 4.8%	486,227 $13.9 Million
Q1 2024 May 14, 2024	SELL	$27.7 - $35.48 $485,193 - $621,467	-17,516 Reduced 3.32%	510,745 $14.9 Million
Q4 2023 Feb 13, 2024	BUY	$26.32 - $34.31 $647,445 - $843,991	24,599 Added 4.88%	528,261 $17.8 Million
Q3 2023 Nov 13, 2023	BUY	$30.68 - $40.09 $102,011 - $133,299	3,325 Added 0.66%	503,662 $15.5 Million
Q2 2023 Aug 11, 2023	SELL	$36.12 - $47.5 $363,945 - $478,610	-10,076 Reduced 1.97%	500,337 $20 Million
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $165,143 - $201,630	4,648 Added 0.92%	510,413 $20.8 Million
Q4 2022 Feb 13, 2023	BUY	$38.19 - $57.45 $517,894 - $779,079	13,561 Added 2.76%	505,765 $19.5 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $72,402 - $83,211	1,413 Added 0.29%	492,204 $26.2 Million
Q2 2022 Aug 12, 2022	SELL	$51.49 - $81.64 $386,380 - $612,626	-7,504 Reduced 1.51%	490,791 $28.6 Million
Q1 2022 May 13, 2022	SELL	$60.03 - $76.49 $699,169 - $890,879	-11,647 Reduced 2.28%	498,295 $38 Million
Q4 2021 Feb 08, 2022	SELL	$47.97 - $62.21 $595,019 - $771,652	-12,404 Reduced 2.37%	509,942 $30.7 Million
Q3 2021 Nov 15, 2021	SELL	$54.64 - $61.3 $284,073 - $318,698	-5,199 Reduced 0.99%	522,346 $29.3 Million
Q2 2021 Aug 13, 2021	SELL	$59.18 - $69.99 $187,245 - $221,448	-3,164 Reduced 0.6%	527,545 $32 Million
Q1 2021 May 12, 2021	SELL	$59.31 - $78.82 $1.56 Million - $2.07 Million	-26,250 Reduced 4.71%	530,709 $37.2 Million
Q4 2020 Feb 11, 2021	SELL	$50.47 - $66.26 $599,230 - $786,704	-11,873 Reduced 2.09%	556,959 $33.3 Million
Q3 2020 Nov 16, 2020	SELL	$51.97 - $63.0 $1.28 Million - $1.55 Million	-24,599 Reduced 4.15%	568,832 $34.2 Million
Q2 2020 Aug 14, 2020	BUY	$30.8 - $52.47 $1.14 Million - $1.94 Million	36,974 Added 6.64%	593,431 $31.1 Million
Q1 2020 May 14, 2020	BUY	$28.4 - $50.7 $234,981 - $419,491	8,274 Added 1.51%	556,457 $18.7 Million
Q4 2019 Feb 14, 2020	SELL	$36.31 - $46.83 $888,687 - $1.15 Million	-24,475 Reduced 4.27%	548,183 $24.8 Million
Q3 2019 Nov 13, 2019	BUY	$35.66 - $44.99 $1.75 Million - $2.21 Million	49,055 Added 9.37%	572,658 $21.8 Million
Q2 2019 Aug 13, 2019	BUY	$36.57 - $47.97 $43,884 - $57,564	1,200 Added 0.23%	523,603 $22.8 Million
Q1 2019 May 13, 2019	BUY	$36.47 - $42.17 $89,935 - $103,991	2,466 Added 0.47%	522,403 $19.9 Million
Q4 2018 Feb 12, 2019	SELL	$41.31 - $52.16 $85,842 - $108,388	-2,078 Reduced 0.4%	519,937 $22.4 Million
Q3 2018 Nov 14, 2018	BUY	$32.85 - $52.0 $326,299 - $516,516	9,933 Added 1.94%	522,015 $25.7 Million
Q2 2018 Sep 18, 2018	SELL	$27.5 - $39.8 $73,040 - $105,708	-2,656 Reduced 0.52%	512,082 $16.4 Million
Q2 2018 Aug 14, 2018	BUY	$27.5 - $39.8 $647,157 - $936,613	23,533 Added 4.79%	514,738 $16.5 Million
Q1 2018 May 09, 2018	BUY	$29.98 - $46.35 $43,530 - $67,300	1,452 Added 0.3%	491,205 $15.3 Million
Q4 2017 Feb 14, 2018	SELL	$31.85 - $46.95 $282,987 - $417,150	-8,885 Reduced 1.78%	489,753 $22.4 Million
Q3 2017 Nov 13, 2017	BUY	$35.7 - $39.5 $17.8 Million - $19.7 Million	498,638	498,638 $18.7 Million

Others Institutions Holding PCRX

# of Institutions

301

Shares Held

51.5M

Call Options Held

378K

Put Options Held

1.53M

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $666M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Pacira Bio Sciences, Inc. Transaction History